Sp138

IBD YEAR IN REVIEW

Date
May 18, 2024
Explore related products in the following collection:

Presenters

Speaker Image for Uma Mahadevan
University of California san francisco
Speaker Image for Edward Barnes
University of North Carolina School of Medicine

Tracks

Related Products

Thumbnail for COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN’S DISEASE.
COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN’S DISEASE.
INTRODUCTION: Recent guidelines propose a fecal calprotectin (FCP) monitoring strategy in the year after Crohn’s disease (CD) resection for low-risk individuals or those receiving pharmacologic prophylaxis to prevent postoperative recurrence (POR)…
Thumbnail for WOUND HEALING AFTER EPISIOTOMY AND CESAREAN SECTION AMONG WOMEN WITH IBD
WOUND HEALING AFTER EPISIOTOMY AND CESAREAN SECTION AMONG WOMEN WITH IBD
Background: Women with inflammatory bowel disease (IBD) face the complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for perianal disease and perineal trauma…
Thumbnail for ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY
ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY
Background: We compared real-world outcomes of upadacitinib (upa) vs tofacitinib (tofa) for ulcerative colitis (UC) through 52 weeks…